on EnVVeno Medical Corporation (NASDAQ:NVNO)
EnVVeno Medical Reports Q3 2025 Financial Results
enVVeno Medical Corporation has revealed its third-quarter 2025 financial results, maintaining a cash reserve of $31.0 million. This reserve is expected to support the company through the second quarter of 2027, excluding the costs associated with the VenoValve commercialization and the enVVe IDE study. The company's cash burn rate for the quarter was $4.2 million, aligning with projections of $4-5 million per quarter.
The company reported a net loss of $4.5 million, a reduction from the $5.6 million loss reported in the third quarter of 2024. This improvement is attributed to a decrease in operating expenses by $1.3 million. enVVeno is engaged with the FDA after filing for a supervisory appeal following a not-approvable letter for the VenoValve. A resolution is anticipated by the end of 2025.
The company continues to advance with the enVVe program, having completed necessary preclinical tests and is preparing for an IDE filing contingent on outcomes from the VenoValve appeal.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EnVVeno Medical Corporation news